Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
24
QNRX Quote, Financials, Valuation and Earnings
Last price:
$6.92
Seasonality move
:
-1.09%
Day range:
$5.85 - $7.10
52-week range:
$5.01 - $41.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.97x
Volume:
58.4K
Avg. volume:
170.8K
1-year change:
-31.43%
Market cap:
$14.5M
Revenue:
--
EPS (TTM):
-$460.50
Analysts' Opinion
-
Consensus RatingQuoin Pharmaceuticals Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.67, Quoin Pharmaceuticals Ltd. has an estimated upside of 322.6% from its current price of $7.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $7.02.
Fair Value
-
According to the consensus of 1 analyst, Quoin Pharmaceuticals Ltd. has 322.6% upside to fair value with a price target of $29.67 per share.
QNRX vs. S&P 500
-
Over the past 5 trading days, Quoin Pharmaceuticals Ltd. has underperformed the S&P 500 by -10.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Quoin Pharmaceuticals Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quoin Pharmaceuticals Ltd. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Quoin Pharmaceuticals Ltd. reported revenues of --.
Earnings Growth
-
Quoin Pharmaceuticals Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Quoin Pharmaceuticals Ltd. reported earnings per share of -$2.92.
Enterprise value:
-6.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$100.7K
Return On Assets:
-123.54%
Net Income Margin (TTM):
--
Return On Equity:
-268.87%
Return On Invested Capital:
-268.87%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$103.3K | -$100.5K | -$100.7K | -$25.2K | -$25.2K | |
| Operating Income | -$9.3M | -$9.6M | -$16.4M | -$2.4M | -$4.5M | |
| EBITDA | -$9.2M | -$9.5M | -$16.3M | -$2.4M | -$4.5M | |
| Diluted EPS | -$4.04 | -$14.47 | -$460.50 | -$12.49 | -$2.92 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.5M | $13.4M | $11.3M | $14.9M | $20M | |
| Total Assets | $9.4M | $14.5M | $12.2M | $15.7M | $20.4M | |
| Current Liabilities | $8.7M | $3.5M | $3.6M | $4.2M | $5.5M | |
| Total Liabilities | $8.7M | $7.1M | $6.5M | $6.5M | $7.3M | |
| Total Equity | $657K | $7.4M | $5.7M | $9.2M | $13.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.8M | -$7.9M | -$13.6M | -$2.3M | -$5.1M | |
| Cash From Investing | $2.2M | -$1.9M | -$4.3M | -$3.2M | -$11.4M | |
| Cash From Financing | $5.2M | $11M | $18.2M | $6M | $18.4M | |
| Free Cash Flow | -$7.8M | -$7.9M | -$13.6M | -$2.3M | -$5.1M | |
QNRX
Sector
Market Cap
$14.5M
$23.9M
Price % of 52-Week High
16.79%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-154.97%
-1.88%
1-Year Price Total Return
-31.43%
-18.29%
Beta (5-Year)
1.614
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.15
200-day SMA
Sell
Level
$10.08
Bollinger Bands (100)
Sell
Level
7.28 - 15.12
Chaikin Money Flow
Sell
Level
-21.4M
20-day SMA
Sell
Level
$7.80
Relative Strength Index (RSI14)
Sell
Level
43.58
ADX Line
Buy
Level
11.42
Williams %R
Neutral
Level
-76.5076
50-day SMA
Sell
Level
$8.18
MACD (12, 26)
Sell
Level
-0.55
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
62.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.895)
Sell
CA Score
(Annual)
Level (-4.0232)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.2288)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.
Stock Forecast FAQ
In the current month, QNRX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The QNRX average analyst price target in the past 3 months is $29.67.
-
Where Will Quoin Pharmaceuticals Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quoin Pharmaceuticals Ltd. share price will rise to $29.67 per share over the next 12 months.
-
What Do Analysts Say About Quoin Pharmaceuticals Ltd.?
Analysts are divided on their view about Quoin Pharmaceuticals Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quoin Pharmaceuticals Ltd. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Quoin Pharmaceuticals Ltd.'s Price Target?
The price target for Quoin Pharmaceuticals Ltd. over the next 1-year time period is forecast to be $29.67 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is QNRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quoin Pharmaceuticals Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of QNRX?
You can purchase shares of Quoin Pharmaceuticals Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quoin Pharmaceuticals Ltd. shares.
-
What Is The Quoin Pharmaceuticals Ltd. Share Price Today?
Quoin Pharmaceuticals Ltd. was last trading at $6.92 per share. This represents the most recent stock quote for Quoin Pharmaceuticals Ltd.. Yesterday, Quoin Pharmaceuticals Ltd. closed at $7.02 per share.
-
How To Buy Quoin Pharmaceuticals Ltd. Stock Online?
In order to purchase Quoin Pharmaceuticals Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get QNRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
QNRX
Sector
P/E ratio
--
21.37x
PEG ratio
0.00x
-0.01x
P/B ratio
0.97x
1.72x
Price / LTM sales
--
1.45x
Growth Metrics
QNRX
Sector
Revenue growth
--
3.44%
Earnings growth
76.62%
15.03%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$2.26
-$0.22
Profitability
QNRX
Sector
Profitability FY 2025
-$100.8K
$2.4M
Return on invested capital
-268.87%
-33.32%
Return on assets
-123.54%
-29.45%
Return on equity
-268.87%
-40.29%
Earnings Date
Last Earnings Date
Apr
4
Next Earnings Date
Apr
4
Estimated Next Earnings Date
Jul
4
Balance Sheet
QNRX
Sector
Total cash
$18.7M
$25.7M
Short term investments
$10.4M
$22.7M
Total assets
$20.4M
$70.6M
Long term debt
--
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
